2. Signaling Pathways
  3. Cytoskeleton
  4. Lysyl Oxidase

Lysyl Oxidase

Lysyl oxidase (LOX) was identified as a secreted enzyme that catalyzes the deamination of the ε-amino group of lysine in collagen and elastin monomers, thereby forming covalent cross-links that stabilize collagen and elastin fibers. This is the first step in the cross-linking reaction of collagen and elastin.

Lysyl Oxidase Related Products (3):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-170538
    SNT-5382
    		Inhibitor 99.96%
    SNT-5382 is a lysyl oxidase family (LOX) inhibitor and anti-fibrotic agent. SNT-5382 binds to the LTQ cofactor of LOXL2 and inhibits the enzymatic activities of LOXL3, LOXL4, LOXL1, CYP2C9, and CYP2C19. SNT-5382 reduces cardiac and liver fibrosis as well as collagen crosslinks, and improves cardiac function. SNT-5382 can be used for the research of heart failure, myocardial infarction, and nonalcoholic steatohepatitis-related liver fibrosis.
    SNT-5382
  • HY-127009
    Levoleucovorin
    		Inhibitor 98.53%
    Levoleucovorin (Levofolinic acid; Levofolene) is the pharmacologically and orally active levoisomer of Folinic acid (HY-17556), a synthetic folate analogue. Levoleucovorin can inhibit LOXL2 with an IC50 of 68.81 μM. Levoleucovorin can inhibit cancer cells proliferation, migration and induce apoptosis. Levoleucovorin can be used as a rescue agent for high-dose Methotrexate (HY-14519). Levoleucovorin can reduce the frequency of embryonic malformations. Levoleucovorin can be used for the research of can and endocrinology, such as breast cancer and osteosarcoma.
    Levoleucovorin
  • HY-183644
    LNO 9
    		Inhibitor
    LNO 9 is an orally active LOXL2 inhibitor and NO donor, with an IC50 of 0.17 μM against human LOXL2. LNO 9 competitively binds to the LTQ cofactor of LOXL2 to form an irreversible complex, thereby inhibiting collagen oxidation and abnormal cross-linking. LNO 9 releases nitric oxide (NO) to increase cGMP levels in pulmonary artery smooth muscle cells. LNO 9 inhibits hypoxia-induced collagen modification and possesses vasodilatory activity. LNO 9 ameliorates right ventricular hypertrophy and pulmonary artery medial thickness in rat models induced by hypoxia and Monocrotaline (HY-N0750), and can be used for research on pulmonary hypertension.
    LNO 9